Peloton Wealth Strategists acquired a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 1,808 shares of the company’s stock, valued at approximately $309,000.
A number of other institutional investors have also added to or reduced their stakes in the stock. National Bank of Canada FI purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $286,371,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $269,447,000. Renaissance Technologies LLC grew its position in shares of Johnson & Johnson by 74.1% during the 3rd quarter. Renaissance Technologies LLC now owns 3,044,500 shares of the company’s stock valued at $491,687,000 after purchasing an additional 1,296,100 shares in the last quarter. Invesco Ltd. grew its position in shares of Johnson & Johnson by 11.4% during the 3rd quarter. Invesco Ltd. now owns 11,513,874 shares of the company’s stock valued at $1,859,489,000 after purchasing an additional 1,178,956 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 43,320,776 shares of the company’s stock worth $6,977,300,000 after acquiring an additional 1,106,544 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.
In other news, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The company had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.2 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be given a dividend of $1.13 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio is 57.14%.
A number of analysts have recently issued reports on JNJ shares. Citigroup lifted their price objective on shares of Johnson & Johnson from $203.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, April 20th. Bank of America began coverage on shares of Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating for the company. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Finally, Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $188.57.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.